DBV Technologies Announces Filing of its First Form 10-Q for the First Quarter of 2021

Rhea-AI Summary

DBV Technologies has filed its first Form 10-Q for Q1 2021 with the U.S. SEC. This document is available on both the company's website and the SEC’s website. DBV Technologies is focused on developing Viaskin™, a non-invasive immunotherapy platform aimed at treating food allergies, including ongoing trials for Viaskin Peanut. The company operates globally with headquarters in France and North American operations in New Jersey, and its stock is traded on Euronext Paris and Nasdaq (ticker: DBVT).

Positive

• Successful filing of the first Form 10-Q for Q1 2021, showing compliance and transparency.
• Continued development of Viaskin™, a promising technology for treating food allergies, highlighting ongoing clinical trials.

Negative

• None.

Montrouge, France, May 5, 2021

DBV Technologies Announces Filing of its First Form 10-Q for the First Quarter of 2021

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the filing of its first Form 10-Q for the quarter ended March 31, 2021 with the U.S. Securities and Exchange Commission (SEC).

This document can be accessed on the Investors & Media section of the Company's website at www.dbv-technologies.com. In addition, this Form 10-Q is available on the SEC’s website at www.sec.gov.

About DBV Technologies 
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Summit, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

DBV Investor Relations Contact
Anne Pollak
+ 1 (857) 529-2363
anne.pollak@dbv-technologies.com

DBV Media Contact
Angela Marcucci
+1 (646) 842-2393
angela.marcucci@dbv-technologies.com

 

Attachment

• PDF Version

FAQ

What is the significance of DBV Technologies filing its Form 10-Q on May 5, 2021?

The filing is essential for regulatory compliance, providing transparency about the company's financial condition and operations for Q1 2021.

Where can I find DBV Technologies' Form 10-Q for the first quarter of 2021?

The Form 10-Q can be accessed on DBV Technologies' website and the SEC’s website.

What is Viaskin™ developed by DBV Technologies?

Viaskin™ is an investigational immunotherapy platform aimed at treating food allergies via non-invasive methods.

What clinical trials is DBV Technologies currently conducting?

DBV Technologies is conducting ongoing clinical trials for Viaskin Peanut as part of its food allergies program.

On which stock exchanges is DBV Technologies listed?

DBV Technologies is listed on Euronext Paris and the Nasdaq under the ticker symbol DBVT.